Jan. 31 at 5:17 PM
Change in share price YTD for all comm'l-stage non-oncology focused bios with market caps of
$1 to
$5.5B.
$OCUL is the worst performer YTD. It appears a rumored Sanofi acq north of the
$16/share offered last September fizzled out. Recall Sanofi announced it was buying DVAX last December. Only 10 of 171 new comm'l-stage non-oncology focused bios went to to create meaningful gains for S/Hs by staying independent (0 of 61 in oncology). M&A exits are, overwhelmingly, best for S/Hs historically
$TARS If anyone can explain what's happened here it would be appreciated. Was it the JPM exclusion? The insider sales? The last TARS press release is dated 11/24/25 (2 months ago). We bought TARS last summer for
$40 ish then sold in the high
$50 s only to see TARS run to
$80
$TVTX appears to trade @ reasonable multiples after the FDA extended the FSGS PDUFA back 3 months.
$LGND investors often cite TVTX's royalties due. There's uncertainty but...
Again,
$APLS ?
This is not investment advice. Just sharing
